Alexandre Corthay
Overview
Explore the profile of Alexandre Corthay including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
1477
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Frafjord A, Skarshaug R, Hammarstrom C, Stankovic B, Dorg L, Aamodt H, et al.
Scand J Immunol
. 2020 Apr;
92(1):e12889.
PMID: 32299134
The analysis of tumour-associated macrophages (TAMs) has a high potential to predict cancer recurrence and response to immunotherapy. However, the heterogeneity of TAMs poses a challenge for quantitative and qualitative...
12.
Stankovic B, Bjorhovde H, Skarshaug R, Aamodt H, Frafjord A, Muller E, et al.
Front Immunol
. 2019 Feb;
9:3101.
PMID: 30774636
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death in the world. Immunological analysis of the tumor microenvironment (immunoscore) shows great promise for improved prognosis and prediction...
13.
Muller E, Speth M, Christopoulos P, Lunde A, Avdagic A, Oynebraten I, et al.
Front Immunol
. 2018 Nov;
9:2520.
PMID: 30450098
Triggering or enhancing antitumor activity of tumor-associated macrophages is an attractive strategy for cancer treatment. We have previously shown that the cytokine interferon-γ (IFN-γ), a type II IFN, could synergize...
14.
Haabeth O, Fauskanger M, Manzke M, Lundin K, Corthay A, Bogen B, et al.
Cancer Res
. 2018 May;
78(16):4573-4585.
PMID: 29752262
Tumor-specific CD4 T cells have been shown to mediate efficient antitumor immune responses against cancer. Such responses can occur through direct binding to MHC class II (MHC II)-expressing tumor cells,...
15.
Wold C, Kjeldsen C, Corthay A, Rise F, Christensen B, Duus J, et al.
Carbohydr Polym
. 2018 Feb;
185:27-40.
PMID: 29421057
The aim of this paper was to perform a comprehensive characterization of polysaccharides isolated from the interior (IOI) and exterior (IOE) parts of the fungus Inonotus obliquus. Pre-extraction with DCM...
16.
Kurena B, Muller E, Christopoulos P, Johnsen I, Stankovic B, Oynebraten I, et al.
Front Immunol
. 2017 Dec;
8:1667.
PMID: 29276511
Cytokine gene delivery by viral vectors is a promising novel strategy for cancer immunotherapy. Semliki Forest virus (SFV) has many advantages as a delivery vector, including the ability to (i)...
17.
Christopoulos P, Corthay A, Koutsilieris M
Cancer Treat Rev
. 2017 Dec;
63:79-95.
PMID: 29253837
Despite the major discoveries occurred in oncology the recent years, breast malignancies remain one of the most common causes of cancer-related deaths for women in developed countries. Development of HER2-targeting...
18.
Muller E, Christopoulos P, Halder S, Lunde A, Beraki K, Speth M, et al.
Front Immunol
. 2017 Nov;
8:1383.
PMID: 29123526
Tumor-associated macrophages may either promote or suppress tumor growth depending on their activation status. Interferon-γ (IFN-γ) has been identified as a key factor for inducing tumoricidal M1 phenotype in macrophages....
19.
Speth M, Repnik U, Muller E, Spanier J, Kalinke U, Corthay A, et al.
Mol Pharm
. 2017 Oct;
14(11):4098-4112.
PMID: 28974092
The attenuated live vaccine strain bacille Calmette-Guérin (BCG) is currently the only available vaccine against tuberculosis (TB), but is largely ineffective against adult pulmonary TB, the most common disease form....
20.
Lorvik K, Hammarstrom C, Fauskanger M, Haabeth O, Zangani M, Haraldsen G, et al.
Cancer Res
. 2016 Sep;
76(23):6864-6876.
PMID: 27634753
Adoptive cell therapy (ACT) trials to date have focused on transfer of autologous tumor-specific cytotoxic CD8 T cells; however, the potential of CD4 T helper (Th) cells for ACT is...